Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis
Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis(476 views) Rendina D, De Filippo G, Viceconti R, Soscia E, Sirignano C, Salvatore M, Della Monica M, Scarano G, Mossetti G
Department of Clinical and Experimental Medicine, 'Federico II' University Medical School, Naples, Italy
Paediatric Endocrinology Unit, A.O.R.N. 'G. Rummo', Benevento, Italy
Department of Biomorphological and Functional Science, Department of Diagnostic Imaging and Radiotherapy, 'Federico II' University Medical School, Naples, Italy
National Research Council (CNR) Biostructures and Bioimaging Institute, 'Federico II' University Medical School, Naples, Italy
Medical Genetics Unit, A.O.R.N. 'G. Rummo', Benevento, Italy
References: Castori, M., Sinibaldi, L., Mingarelli, R., Lachman, R.S., Rimoin, D.L., Dallapiccola, B., Pachydermoperiostosis: An update (2005) Clin Gen, 68, pp. 477-48
Auger, M., Stavrianeas, N., Pachydermoperiostosis (2004) Orphanet encyclopedia, , www.orpha.net, Available from:, accessed December 2006
White, M.P., Hereditary metabolic and dysplastic skeletal disorders (2002) Disorders of bone and mineral metabolism, pp. 937-985. , Coe FL, Favus MJ, editors, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins
Jajic, Z., Jajic, I., Nemcic, T., Primary hypertrophic osteoarthropathy: Clinical, radiologic, and scintigraphic characteristics (2001) Arch Med Res, 32, pp. 136-142
Jajic, I., Jajic, Z., Grazio, S., Minor but important symptoms and signs in primary hypertrophic osteoarthropathy (2001) Clin Exp Rheumatol, 19, pp. 357-358
Hughes, H.E., McAlpine, P.J., Cox, D.W., Philipps, S., An autosomal dominant syndrome with 'acromegaloid' features and thickened oral mucosa (1985) J Med Genet, 22, pp. 119-125
Pichler, G., Eber, E., Thalhammer, G., Muntean, W., Zach, M.S., Arthralgia and digital clubbing in a child: Hypertrophic osteoarthropathy with inflammatory pseudotumour of the lung (2004) Scand J Rheumatol, 33, pp. 189-191
Oikarinen, A., Palatsi, R., Kylmaniemi, M., Keski-Oja, J., Risteli, J., Kallioinen, M., Pachydermoperiostosis: Analysis of the connective tissue abnormality in one family (1994) J Am Acad Dermatol, 31, pp. 947-953
Silveri, F., De Angelis, R., Argentati, F., Brecciaroli, D., Muti, S., Cervini, C., Hypertrophic osteoarthropathy: Endothelium and platelet function (1996) Clin Rheumatol, 15, pp. 435-439
Silveira, L.H., Martinez-Lavin, M., Pineda, C., Fonseca, M.C., Navarro, C., Nava, A., Vascular endothelial growth factor and hypertrophic osteoarthropathy (2000) Clin Exp Rheumatol, 18, pp. 57-62
Matucci-Cerinic, M., Martinez-Lavin, M., Rojo, F., Fonseca, C., Kahaleh, B.M., von Willebrand factor antigen in hypertrophic osteoarthropathy (1992) J Rheumatol, 19, pp. 765-767
Fam, A.G., Chin-Sang, H., Ramsay, C.A., Pachydermoperiostosis: Scintigraphic, thermographic, plethysmographic, and capillaroscopic observations (1983) Ann Rheum Dis, 42, pp. 98-102
Kallen, K.J., The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases (2002) Biochim Biophys Acta, 1592, pp. 323-334
Jostock, T., Mullberg, J., Ozbek, S., Atreya, R., Blinn, G., Voltz, N., Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses (2001) Eur J Biochem, 268, pp. 160-167
Boyle, W.J., Simonet, W.S., Lacey, D.L., Osteoclast differentiation and activation (2003) Nature, 423, pp. 337-342
Franchimont, N., Wertz, S., Malaise, M., Interleukin-6: An osteotropic factor influencing bone formation? (2005) Bone, 37, pp. 601-606
Jones, S.A., Rose-John, S., The role of soluble receptors in cytokine biology: The agonistic properties of the sIL-6R/IL-6 complex (2002) Biochim Biophys Acta, 1592, pp. 251-263
Kwan Tat, S., Padrines, M., Theoleyre, S., Heymann, D., Fortun, Y., IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology (2004) Cytokine Growth Factor Rev, 15, pp. 49-60
Mossetti, G., Rendina, D., De Filippo, G., Viceconti, R., Di Domenico, G., Cioffi, M., Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: Relationship to risedronate treatment (2005) Bone, 36, pp. 549-554
Angelo, L.S., Kurzrock, R., Vascular endothelial growth factor and its relationship to inflammatory mediators (2007) Clin Cancer Res, 13, pp. 2825-2830
Knudsen, L.S., Ostergaard, M., Baslund, B., Narvestad, E., Petersen, J., Nielsen, H.J., Plasma IL-6, plasma VEGF, and serum YKL-40: Relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate (2006) Scand J Rheumatol, 35, pp. 489-491
Brandi, M.L., Collin-Osdoby, P., Vascular biology and the skeleton (2006) J Bone Miner Res, 21, pp. 183-192
Roodman, G.D., Treatment strategies for bone disease (2007) Bone Marrow Transplant, 4, pp. 1139-1146
White, M. P., Hereditary metabolic and dysplastic skeletal disorders (2002) Disorders of bone and mineral metabolism, pp. 937-985. , Coe FL, Favus MJ, editors, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins
Hughes, H. E., McAlpine, P. J., Cox, D. W., Philipps, S., An autosomal dominant syndrome with 'Acromegaloid' features and thickened oral mucosa (1985) J Med Genet, 22, pp. 119-125
Silveira, L. H., Martinez-Lavin, M., Pineda, C., Fonseca, M. C., Navarro, C., Nava, A., Vascular endothelial growth factor and hypertrophic osteoarthropathy (2000) Clin Exp Rheumatol, 18, pp. 57-62
Fam, A. G., Chin-Sang, H., Ramsay, C. A., Pachydermoperiostosis: Scintigraphic, thermographic, plethysmographic, and capillaroscopic observations (1983) Ann Rheum Dis, 42, pp. 98-102
Kallen, K. J., The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases (2002) Biochim Biophys Acta, 1592, pp. 323-334
Boyle, W. J., Simonet, W. S., Lacey, D. L., Osteoclast differentiation and activation (2003) Nature, 423, pp. 337-342
Jones, S. A., Rose-John, S., The role of soluble receptors in cytokine biology: The agonistic properties of the sIL-6R/IL-6 complex (2002) Biochim Biophys Acta, 1592, pp. 251-263
Angelo, L. S., Kurzrock, R., Vascular endothelial growth factor and its relationship to inflammatory mediators (2007) Clin Cancer Res, 13, pp. 2825-2830
Knudsen, L. S., Ostergaard, M., Baslund, B., Narvestad, E., Petersen, J., Nielsen, H. J., Plasma IL-6, plasma VEGF, and serum YKL-40: Relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate (2006) Scand J Rheumatol, 35, pp. 489-491
Brandi, M. L., Collin-Osdoby, P., Vascular biology and the skeleton (2006) J Bone Miner Res, 21, pp. 183-192
Roodman, G. D., Treatment strategies for bone disease (2007) Bone Marrow Transplant, 4, pp. 1139-1146
Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis
Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis
No results.
Interleukin (il)-6 And Receptor Activator Of Nuclear Factor (nf)-Kappab Ligand (rankl) Are Increased In The Serum Of A Patient With Primary Pachydermoperiostosis